PARSIPPANY, N.J. — Daiichi Sankyo's SVP commercial operations has taken on a new role at the company.
The drug maker said that John Gargiulo would become president and CEO, effective Monday, following the retirement of current leader Joseph Pieroni.
Gargiulo has been with Daiichi Sankyo since its inception in 1996. In addition to his role at the company, he currently serves on the board of directors of the Pharmaceutical Research and Manufacturers Association, as well as the National Pharmaceutical Council.
"I am excited about leading DSI through our next company milestones and fostering a continuing vision of employee excellence that will drive DSI growth and success," Gargiulo said.